EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

Journal of Drug Targeting

Volumn 14, Issue 4, 2006, Pages 215-223

  Mamot, Christoph ^a,b   Ritschard, Reto ^b   Küng, Willy ^b   Park, John W ^c   Herrmann, Richard ^a   Rochlitz, Christoph F ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug delivery; Epidermal growth factor receptor (EGFR); Immunoliposomes; Liposomes; Monoclonal antibodies

Indexed keywords

ADRIBLASTIN RD; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOLIPOSOME; MATUZUMAB; PANITUMUMAB;

ARTICLE; CANCER CELL CULTURE; CELL TRANSPORT; COLORECTAL CANCER; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33745284972     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600691049     Document Type: Article

References (24)

1. Allen TM and Martin, FJ. (2004) Advantages of liposomal delivery systems for anthracyclines Semin Oncol, 31, pp. 5-15.
2. Bier, H and Hoffmann, T and Hauser, U and Wink, M and Ochler, M and Kovar, A and Muser, M and Knecht, R. (2001) Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx Cancer Chemother Pharmacol, 47, pp. 519- 524.
3. Claassen, E. (1992) Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics J Immunol Methods, 147, pp. 231-240.
4. Cunningham, D and Humblet, Y and Siena, S and Khayat, D and Bleiberg, H and Santoro, A and Bets, D and Mueser, M and Harstrick, A and Verslype, C and Chau, I and Van Cutsem, E. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med, 351, pp. 337-345.
5. El-Rayes, BF and LoRusso, PM. (2004) Targeting the epidermal growth factor receptor Br J Cancer, 91, pp. 418-424.
6. Fan, Z and Masui, H and Altas, I and Mendelsohn, J. (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res, 53, pp. 4322-4328.
7. Gabizon, A and Shmeeda, H and Horowitz, AT and Zalipsky, S. (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates Adv Drug Deliv Rev, 56, pp. 1177-1192.
8. Garrido, C and Chauffert, B and Pinard, D and Tibaut, F and Genne, P and Assem, M and Dimanche-Boitrel, MT. (1995) Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line Int J Cancer, 61, pp. 873-879.
9. Haran, G and Cohen, R and Bar, LK and Barenholz, Y. (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim Biophys Acta, 1151, pp. 201-215.
10. Kirpotin, D and Park, JW and Hong, K and Zalipsky, S and Li, WL and Carter, P and Benz, CC and Papahadjopoulos, D. (1997) Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro Biochem, 36, pp. 66-75.
11. Lasic, DD and Frederik, PM and Stuart, MC and Barenholz, Y and McIntosh, TJ. (1992) Gelation of liposome interior. A novel method for drug encapsulation FEBS Lett, 312, pp. 255-258.
12. Litzinger, DC and Buiting, AM and van Rooijen, N and Huang, L. (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes Biochim Biophys Acta, 1190, pp. 99-107.
13. Mamot, C and Drummond, DC and Greiser, U and Hong, K and Kirpotin, DB and Marks, JD and Park, JW. (2003a) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res, 63, pp. 3154-3161.
14. Mamot, C and Drummond, DC and Hong, K and Kirpotin, DB and Park, JW. (2003b) Liposome-based approaches to overcome anticancer drug resistance Drug Resist Updat, 6, pp. 271-279.
15. Mamot, C and Drummond, DC and Noble, CO and Kallab, V and Guo, Z and Hong, K and Kirpotin, DB and Park, JW. (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res, 65, pp. 11631-11638.
16. Mendelsohn, J. (2002) Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol, 20, pp. 1S-13S.
17. Noble, CO and Kirpotin, DB and Hayes, ME and Mamot, C and Hong, K and Park, JW and Benz, CC and Marks, JD and Drummond, DC. (2004) Development of ligand-targeted liposomes for cancer therapy Expert Opin Ther Targets, 8, pp. 335-353.
18. Park, JW and Hong, K and Kirpotin, DB and Colbern, G and Shalaby, R and Baselga, J and Shao, Y and Nielsen, UB and Marks, JD and Moore, D and Papahadjopoulos, D and Benz, CC. (2002) Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery Clin Cancer Res, 8, pp. 1172-1181.
19. Prenzel, N and Fischer, OM and Streit, S and Hart, S and Ullrich, A. (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer, 8, pp. 11-31.
20. Scudiero, DA and Shoemaker, RH and Paull, KD and Monks, A and Tierney, S and Nofziger, TH and Currens, MJ and Seniff, D and Boyd, MR. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res, 48, pp. 4827-4833.
21. Selvaggi, G and Novello, S and Torri, V and Leonardo, E and De Giuli, P and Borasio, P and Mossetti, C and Ardissone, F and Lausi, P and Scagliotti, GV. (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol, 15, pp. 28-32.
22. Spano, JP and Lagorce, C and Atlan, D and Milano, G and Domont, J and Benamouzig, R and Attar, A and Benichou, J and Martin, A and Morere, JF and Raphael, M and Penault-Llorca, F and Breau, JL and Fagard, R and Khayat, D and Wind, P. (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol, 16, pp. 102-108.
23. Szoka, F and Olson, F and Heath, T and Vail, W and Mayhew, E and Papahadjopoulos, D. (1980) Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes Biochim Biophys Acta, 601, pp. 559-571.
24. Vanhoefer, U and Tewes, M and Rojo, F and Dirsch, O and Schleucher, N and Rosen, O and Tillner, J and Kovar, A and Braun, AH and Trarbach, T and Seeber, S and Harstrick, A and Baselga, J. (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol, 22, pp. 175-184.